Metformin and Amoxicillin/Clavulanate as Co-Administration for the Treatment of Hyperglycemia in Female Rats Caused by Alloxan.

Diabetes mellitus (DM) or hyperglycemia is spreading quickly worldwide. When infections coexist, the oral hypoglycemic medication metformin is co-administered with an antimicrobial agent. The current study examined the effects of co-administering Amoxicillin/Clavulanate (AMC) and metformin in female rats with alloxan-induced diabetes. AMC is an antibiotic used to treat inflammation. Rats used in the study were separated into five groups of five albino rats each. Tap water and the same meal were given to group I negative control without any treatment. Group II positive control administrations of alloxan monohydrate 200 mg/kg body weight allowance, recipients in group three receiving 625 mg of AMC over the course of two weeks, and recipients in groups four receiving metformin form in 500 mg/kg with alloxan A last group V recipient will take AMC, metformin, and alloxan for two weeks. On days 0, 7, and 14, measurements of serum glucose, total cholesterol, triglycerides, and electrolytes (Cl-, Na+, and K+) were made. Samples of blood were collected weekly and parameters were measured. Results revealed no discernible change in total cholesterol, triglycerides, or electrolytes chloride and potassium. When compared to rats treated with metformin and alloxan, animals treated with AMC. These results indicate that the glucose-depletion impact of metformin could be accelerated by co-administration with the AMC. Low levels of sugar and sodium have been observed of animals caused by diabetes with alloxan.